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To estimate the prevalence of extensively drug-resistant 
tuberculosis (XDR TB) in China, we retrospectively analyzed 
drug-resistance proﬁ   les of 989 clinical Mycobacterium 
tuberculosis isolates. We found 319 (32.3%) isolates 
resistant to >1 ﬁ  rst-line drugs; 107 (10.8%) isolates were 
multidrug resistant, of which 20 (18.7%) were XDR. XDR TB 
is of major concern in China.
E
xtensively drug-resistant (XDR) tuberculosis (TB), 
a severe form of TB disease, is deﬁ  ned as TB that 
is resistant to at least rifampin and isoniazid (multidrug 
resistant [MDR]), as well as to any member of the quinolone 
family and at least 1 second-line anti-TB injectable drug: 
kanamycin, capreomycin, or amikacin (1,2). According 
to the World Health Organization (WHO), XDR TB has 
been reported in 57 countries and is a major concern for 
global health (2,3). The WHO Global Task Force on XDR 
TB has recommended laboratory-based surveillance to 
better understand the prevalence of XDR TB in developing 
countries (4). However, surveillance data on XDR TB 
from People’s Republic of China remain scant. Shandong 
Province is the second largest province in China, with a 
population of 94 million. Shandong Provincial Chest 
Hospital (SPCH) is the only provincial-level hospital 
specializing in TB clinical service and control. In 
collaboration with     the SPCH TB reference laboratory, we 
retrospectively analyzed the drug-resistance proﬁ  les of a 
group of clinical Mycobacterium tuberculosis isolates to 
estimate the prevalence of XDR TB in China.
The Study
During November 2004–April 2007, a total of 989 
clinical M. tuberculosis isolates were cultured and examined 
by  ﬁ  rst- and second-line anti-TB drug susceptibility test 
(DST) at the SPCH TB reference laboratory. These isolates 
were collected from 989 inpatients (mean age ± SD 40.1 ± 
18.9 years; range 0.3–88 years; 65.5% male) at the SPCH,; 
these patients represented 860 (87.0%) new and 129 (13.0%) 
retreatment TB cases. The DST was performed according 
to WHO-recommended standard procedures, and quality 
control was conducted by interlaboratory conﬁ  rmation tests 
with WHO-recognized reference laboratories in South Korea 
and Hong Kong Special Administrative Region, China 
(5,6). The DST panel included 4 ﬁ  rst-line anti-TB drugs: 
isoniazid, rifampin, streptomycin, and ethambutol, and 5 
second-line drugs: para-aminosalicylic acid, ciproﬂ  oxacin, 
levoﬂ   oxacin, amikacin, and capreomycin. Kanamycin 
was not included in the DST panel because it is rarely 
used to treat TB disease in this study population because 
of side effects. Because levoﬂ   oxacin and ciproﬂ  oxacin 
are  ﬂ   uoroquinolones with full cross-resistance, they 
were considered as the same family of anti-TB drugs and 
represented by ﬂ  uoroquinolones in our analysis.
Among the 989 M. tuberculosis isolates, the overall 
proportion of ﬁ  rst-line drug resistance (at least 1 drug) 
was 32.3% (319/989). streptomycin had the highest rate 
of resistance (24.1%), followed by isoniazid (18.9%), 
rifampin (16.1%), and ethambutol (4.7%). A total of 107 
(10.8%) isolates were resistant to at least isoniazid and 
rifampin (MDR). Thirty-one (3.1%) isolates were resistant 
to all ﬁ  rst-line drugs (Table 1). Eighty-three MDR isolates 
(77.6%) were identiﬁ  ed from new TB case-patients. The 
overall rate of second-line drug resistance was 19.1% 
(189/989). Fluoroquinolones had the highest rate of 
resistance (16.4%), followed by capreomycin (5.7%), para-
aminosalicylic acid (3.7%), and amikacin (3.2%). A total of 
27 (2.7%) isolates were resistant to >3 second-line drugs.
Among the 107 MDR isolates, 60.7% (65/107) were 
resistant to at least 1 second-line drug, and 53.3% (57/107) 
were resistant to ﬂ  uoroquinolones. A total of 20 (18.7%) 
MDR isolates met the deﬁ  nition of XDR TB (resistant to 
any ﬂ  uoroquinolones and at least 1 injectable drug) (Table 
2). Among 20 XDR isolates, 11 were resistant to 4 ﬁ  rst-
line anti-TB drugs and 10 to >6 ﬁ   rst- and second-line 
anti-TB drugs. The 20 XDR isolates were cultured from 
the sputum specimens of 20 patients with pulmonary TB 
(mean age ± SD 47.0 ± 15.8 years; range 18–68 years; 11 
male). Seventeen patients with XDR TB were receiving 
retreatment and had 4–30-year histories of chronic TB and 
had been previously treated with second-line anti-TB drugs. 
Three patients with XDR TB had new cases without prior 
anti-TB treatment. Contact investigations did not identify 
epidemiologic links among these patients with XDR TB.
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The Global Project on Anti-tuberculosis Drug 
Resistance Surveillance (2002–2007, 37 countries) has 
reported that XDR TB prevalence among MDR TB cases 
ranged from 6.6% to 23.7% worldwide (1). The most 
recent surveillance data from Beijing and Shanghai, China, 
showed that the XDR TB cases accounted for ≈6.3% of 
MDR TB cases in both cities (7,8). By analyzing ﬁ  rst- 
and second-line drug resistance proﬁ  les of 989 clinical M. 
tuberculosis isolates in a clinical laboratory of Shandong 
Province, we showed that 18.7% of MDR strains met the 
deﬁ  nition for XDR, which is relatively higher than the 
previous surveillance data in China (7,8). Several issues 
might explain this deviation. First, the data from Shanghai 
were obtained through a population-based Shanghai Center 
for Disease Control surveillance mechanism that included 
general hospitals, TB clinics, and community health centers, 
whereas our data were obtained through a TB hospital–
based surveillance study with a relatively higher proportion 
of previously treated patients (chronic or refractory TB cases 
with prior anti-TB treatment) than in the Shanghai study. 
Therefore, the data from our study may overestimate the 
prevalence of XDR and MDR TB in Shandong Province. 
Second, the data from the Beijing study also were obtained 
through a TB hospital–based surveillance study. However, 
the DST panel did not include capreomycin, which may 
have led to an underestimation of the XDR TB prevalence 
among inpatients of this TB hospital.
The susceptibility testing of second-line anti-TB drugs 
has not been standardized (9,10). Because second-line anti-
TB drugs are being prescribed more frequently in current 
clinical practice, quality assurance and clinical correlation 
of second-line DST are urgently needed to provide reliable 
evidence for clinical management of XDR TB (9,10).
The current standard care of TB patients in China 
(National Tuberculosis Program) does not include the ﬁ  rst- 
and second-line anti-TB DST because of its prohibitive 
cost. In the current study, 15.0% of XDR and 77.6% of 
MDR isolates were obtained from persons for whom 
TB was newly diagnosed and who had received no prior 
anti-TB treatment (i.e., had primary drug resistance). The 
surveillance data from Shanghai have also shown that more 
than half of XDR and MDR TB cases occurred in patients 
for whom TB was newly diagnosed (8). These results 
clearly indicate that the transmission of drug-resistant TB 
among Chinese populations is extensive and widespread, 
which highlights a need for TB control policy reform in 
China to face this emerging challenge.
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Table 1. First- and second-line drug resistance of 989 clinical 
Mycobacterium tuberculosis isolates, People’s Republic of China, 
November 2004–April 2007* 
Drugs*  No. isolates Rate, % 
Overall first-line drug resistance  319 32.3
  INH  187 (44)  18.9 (4.4) 
  RFP  159 (16)  16.1 (1.6) 
  EMB  46 (0)  4.7 (0) 
  SM  238 (78)  24.1 (7.9) 
MDR, overall  107 10.8
  INH + RFP  16 1.6
  INH + RFP + EMB  2 0.2
  INH + RFP + SM  58 5.9
  INH + RFP + EMB + SM  31 3.1
Overall second-line drug resistance  189 19.1
  FQ  162 (103)  16.4 (10.4) 
  AMK  32 (0)  3.2 (0) 
  CPM  56 (14)  5.7 (1.4) 
  PAS  37 (6)  3.7 (0.6) 
Second-line drug polyresistance  66 6.6
  FQ + AMK  8 0.8
  FQ + AMK + CPM  9 0.9
  FQ + AMK + PAS  4 0.4
  FQ + AMK + CPM + PAS  6 0.6
  FQ + CPM  15 1.5
  FQ + PAS  10 1.0
  FQ + CPM + PAS  7 0.7
  AMK + CPM  3 0.3
  AMK + PAS  1 0.1
  AMK + CPM + PAS  1 0.1
  CPM + PAS  2 0.2
*Numbers and rates of mono–first- and -second–line drug-resistant strains 
shown in parentheses. INH, isoniazid; RFP, rifampin;, EMB, ethambutol; 
SM, streptomycin; MDR, multidrug-resistant; FQ, fluoroquinolines 
(specifically ciprofloxacin and levofloxacin); AMK, amikacin; CPM, 
capreomycin; PAS, para-aminosalicylic acid. 
Table 2. Second-line drug resistance of 107 MDR Mycobacterium 
tuberculosis isolates, People’s Republic of China, November 
2004–April 2007* 
Drugs  No. isolates  Rate, % 
Overall second-line drug resistance  65 60.7
 FQ  57 53.3
 AMK  19 17.8
 CPM  24 22.4
 PAS  18 16.8
XDR, total  20 18.7
  FQ + AMK  4 3.7
  FQ + CPM  4 3.7
  FQ + AMK + CPM  5 4.7
  FQ + AMK + PAS  2 1.9
  FQ + CPM + PAS  3 2.8
  FQ + AMK + CPM + PAS  2 1.9
*MDR, multidrug-resistant; FQ, fluoroquinolines (specifically ciprofloxacin 
and levofloxacin); AMK, amikacin; CPM, capreomycin; PAS, para-
aminosalicylic acid; XDR, extensively drug-resistant. XDR TB, China
primary research interest is the epidemiology of drug-resistant M. 
tuberculosis.
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